• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Randy Osborne

Articles by Randy Osborne

Vividion hatches series B: $82M funds 'golden eggs' trio bound for POC work

May 1, 2019
By Randy Osborne
Vividion Therapeutics Inc. CEO Diego Miralles told BioWorld that $82 million in new series B money will propel research to "clinical proof of concept in at least one of the three lead programs, if not more" as the company – just over a year after sealing a pact worth $101 million up front that brought Celgene Corp. aboard as a collaborator – pulled off an oversubscribed round with its partner on board.
Read More

Satsuma peels out, raising $62M in migraine series B; phase III plan takes shape

May 1, 2019
By Randy Osborne
Satsuma Pharmaceuticals Inc. CEO John Kollins told BioWorld Asia the migraine space may be in a stage of development similar to the depression therapeutic area before the advent of selective serotonin reuptake inhibitors, and his firm's dry-powder inhaled STS-101 (dihydroergotamine [DHE]) could help turn the corner in acute treatment of headaches.
Read More

RET butler serves up data, Loxo gone with the wind? Blueprint seen 'closing in'

April 30, 2019
By Randy Osborne
The disclosure in late March by Blueprint Medicines Corp. that, based on talks with regulators, the Cambridge, Mass.-based firm will expedite development of avapritinib, BLU-667 and BLU-782 served to whet investor appetite and fuel speculation about the competitive chances of one candidate in particular.
Read More

PRV-powered rimegepant nears NDA as speculation on Biohaven still simmers

April 29, 2019
By Randy Osborne
The start in early April by Biohaven Pharmaceutical Holding Co. Ltd. of the phase II/III trial with BHV-3500 in acute treatment of migraine brought renewed attention to the calcitonin gene-related peptide (CGRP) receptor antagonist space, even as rumors swirled later in the month that the New Haven, Conn.-based firm was mulling a sale – if not of the company, then of its CGRP platform.
Read More

Satsuma peels out, raising $62M in migraine series B; phase III plan takes shape

April 25, 2019
By Randy Osborne

Satsuma peels out, raising $62M in migraine series B; phase III plan takes shape

April 25, 2019
By Randy Osborne
Satsuma Pharmaceuticals Inc. CEO John Kollins told BioWorld the migraine space may be in a stage of development similar to the depression therapeutic area before the advent of selective serotonin reuptake inhibitors, and his firm's dry-powder inhaled STS-101 (dihydroergotamine [DHE]) could help turn the corner in acute treatment of headaches.
Read More

Nix BP tick-spit ipse dixit: Akari charivari hails dual binder's skin disease win

April 24, 2019
By Randy Osborne
Akari Therapeutics plc's interim CEO and chief operating officer, Clive Richardson, told BioWorld that the company plans to enroll more seriously afflicted bullous pemphigoid (BP) patients in the phase II trial that has yielded positive results in three subjects treated with the firm's once-daily subcutaneous therapy, nomacopan (previously known as coversin), based on a protein originally discovered in the saliva of the Ornithodoros moubata tick. "Hopefully on the back of that expanded trial we would go to the FDA early next year and agree with them [on] what would be the pathway to a pivotal study," he said.
Read More

Bank shot: KRAS-pocket players chasing money as new target results pooled

April 23, 2019
By Randy Osborne
A rivalry is shaping up between heavyweight Amgen Inc. and smaller contender Mirati Therapeutics Inc. in the targeting of KRAS G12C, a protein that researchers once believed altogether intractable because it is lacking in hydrophobic pockets and binding grooves.
Read More

Muscle-tussle slip benefit for Regeneron; Acceleron not to worry with backup

April 22, 2019
By Randy Osborne
Word hardly shook the world in early April when Cambridge, Mass.-based Acceleron Pharma Inc. dropped ACE-2494, a systemic muscle agent in phase I tests in healthy volunteers, because anti-drug antibodies (ADAs) developed. Although the compound had shown signs of early target engagement and ADAs had not been associated with any adverse event, Acceleron said the candidate wasn't worth going ahead with.
Read More

HD TV? Wave airs phase I data in DMD, stock slides; some investors tuning out

April 17, 2019
By Randy Osborne
Although analysts urged a more moderate stance, investors sheared Wave Life Sciences Ltd.'s stock, apparently displeased with final results from the phase I trial with suvodirsen, or WVE-210201, in Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
Read More
Previous 1 2 … 129 130 131 132 133 134 135 136 137 … 452 453 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 22, 2025.
  • Brain with handshake and cityscape

    Vigil takeover brings TREM2 Alzheimer’s prospect to Sanofi

    BioWorld
    Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe